Phase III SINDAS: Interim Analysis of First-line EGFR TKI With vs Without SBRT in Patients With EGFR-Mutated Oligometastatic NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
Addition of SBRT to first-line EGFR TKI significantly prolonged PFS and OS vs EGFR TKI alone in Chinese patients with EGFR-mutated oligometastatic NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: June 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

DESTINY-Lung02 interim analyses: efficacy/safety of 2 doses of T-DXd (5.4 mg/kg and 6.4 mg/kg) in patients with HER2-mutated NSCLC and at least 1 previous therapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 26, 2022

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: September 26, 2022

Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)

Narjust Florez, MD Released: September 23, 2022

Phase III CodeBreaK 200 study of sotorasib vs docetaxel in previously treated KRAS G12C-mutated advanced non-small-cell lung cancer, presented at ESMO 2022 as reported by Clinical Care Options (CCO)

Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings